Early research (Phase 1)Looking for participantsNCT06610799What this trial is testingStudy of IBI363 in Patients with Advanced First-line Gastric CancerWho this might be right forIBI363 + Chemotherapy Xiangdong Cheng 40
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07342725What this trial is testingPhase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic CancerWho this might be right forPancreatic Cancer Metastatic Ruijin Hospital 48
Testing effectiveness (Phase 2)Looking for participantsNCT07122687What this trial is testingIBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerWho this might be right forResectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer Innovent Biologics (Suzhou) Co. Ltd. 170
Testing effectiveness (Phase 2)Looking for participantsNCT07325630What this trial is testingPerioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric CancerWho this might be right forIBI363 + Chemotherapy Zhejiang Cancer Hospital 60
Testing effectiveness (Phase 2)Looking for participantsNCT07408635What this trial is testingIBI363 (PD-1/IL-2α-bias) in Combination With Chemotherapy as Neoadjuvant Therapy in Initially Unresectable Stage III Non-Small Cell Lung CancerWho this might be right forUnresectable Stage III Non-small Cell Lung CancerCarcinoma, Non-Small-Cell Lung Cancer (NSCLC) Shanghai Pulmonary Hospital, Shanghai, China 43